Vivo Bio Tech Intrinsic Value
Vivo Bio Tech (VIVOBIOT) median intrinsic value is ₹48.22 from 4 valuation models (range ₹39–₹48), vs current price ₹19.29 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Read VIVOBIOT dividend growth for the complete payout history and dividend yield track record.
VIVOBIOT Valuation Methods Summary — DCF, Graham Number & P/E
Vivo Bio Tech intrinsic value across 4 models vs current price ₹19.29 — upside/downside and value range per method. Analyse Vivo Bio Tech shareholding analysis to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹48.22 | ₹43.40 - ₹53.04 | +150.0% | Book Value/Share: ₹41.82, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹38.58 | ₹34.72 - ₹42.44 | +100.0% | Revenue/Share: ₹25.45, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹38.58 | ₹34.72 - ₹42.44 | +100.0% | EBITDA: ₹20.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹48.22 | ₹38.58 - ₹57.86 | +150.0% | CF Growth: 5.0%, Discount: 15% |
VIVOBIOT Intrinsic Value vs Market Price — All Valuation Models
Vivo Bio Tech fair value range ₹39–₹48 vs current market price ₹19.29 across 4 valuation models. For current market price and key ratios, visit Vivo Bio Tech share price chart.
VIVOBIOT Intrinsic Value Analysis — Undervalued or Overvalued?
Vivo Bio Tech median intrinsic value ₹48.22, current price ₹19.29 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of VIVOBIOT?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Vivo Bio Tech (VIVOBIOT) is ₹48.22 (median value). With the current market price of ₹19.29, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹38.58 to ₹48.22, indicating ₹38.58 - ₹48.22.
Is VIVOBIOT undervalued or overvalued?
Based on our multi-method analysis, Vivo Bio Tech (VIVOBIOT) appears to be trading below calculated value by approximately 150.0%.
VIVOBIOT Financial Health — Key Ratios vs Industry Benchmarks
Vivo Bio Tech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.51 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | -21.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 31.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.31x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
VIVOBIOT Cash Flow Quality — Operating & Free Cash Flow
Vivo Bio Tech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹12 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹16 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹15 Cr | ₹13 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹17 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹14 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |